Vertex Pharmaceuticals Inc
VRTX477.920USD
+19.110+4.17%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
121.37BMarket Cap
33.40P/E TTM
More Details of Vertex Pharmaceuticals Inc Company
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Inc Info
Ticker SymbolVRTX
Company nameVertex Pharmaceuticals Inc
IPO dateJul 24, 1991
CEOKewalramani (Reshma)
Number of employees6100
Security typeOrdinary Share
Fiscal year-endJul 24
Address50 Northern Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone16173416393
Websitehttps://www.vrtx.com/
Ticker SymbolVRTX
IPO dateJul 24, 1991
CEOKewalramani (Reshma)
Company Executives of Vertex Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
90.67K
+38857.00%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+5000.00%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
44.00K
+11333.00%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
33.48K
+9012.00%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
33.05K
+7249.00%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
24.37K
+9068.00%
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
22.93K
+6800.00%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
-800.00%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.57K
-266.00%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+796.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
90.67K
+38857.00%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+5000.00%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
44.00K
+11333.00%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
33.48K
+9012.00%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
33.05K
+7249.00%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
24.37K
+9068.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
TRIKAFTA
2.65B
86.26%
ALYFTREK
247.00M
8.03%
Other CF products
175.80M
5.71%
By RegionUSD
Name
Revenue
Proportion
United States
1.98B
64.24%
Europe
836.90M
27.20%
Other
263.20M
8.56%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
TRIKAFTA
2.65B
86.26%
ALYFTREK
247.00M
8.03%
Other CF products
175.80M
5.71%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.45%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
Other
63.53%
Shareholders
Shareholders
Proportion
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.45%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
Other
63.53%
Shareholder Types
Shareholders
Proportion
Investment Advisor
60.46%
Investment Advisor/Hedge Fund
27.86%
Pension Fund
2.37%
Research Firm
2.35%
Bank and Trust
2.10%
Sovereign Wealth Fund
1.50%
Hedge Fund
1.14%
Individual Investor
0.19%
Insurance Company
0.06%
Other
1.96%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
2986
248.55M
97.96%
-4.86M
2025Q3
2933
249.27M
98.24%
-2.14M
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
25.91M
10.21%
-2.82M
-9.82%
Sep 30, 2025
The Vanguard Group, Inc.
24.10M
9.5%
+240.67K
+1.01%
Sep 30, 2025
Capital Research Global Investors
16.55M
6.52%
+444.99K
+2.76%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
14.47M
5.7%
+317.50K
+2.24%
Sep 30, 2025
State Street Investment Management (US)
11.61M
4.57%
-169.23K
-1.44%
Sep 30, 2025
Geode Capital Management, L.L.C.
5.97M
2.35%
+45.00K
+0.76%
Sep 30, 2025
Invesco Capital Management (QQQ Trust)
5.69M
2.24%
+318.09K
+5.92%
Dec 31, 2025
Wellington Management Company, LLP
4.77M
1.88%
-41.34K
-0.86%
Sep 30, 2025
Capital International Investors
4.69M
1.85%
+2.05M
+77.89%
Sep 30, 2025
AllianceBernstein L.P.
4.52M
1.78%
+144.27K
+3.30%
Sep 30, 2025
View more
Related ETFs
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Name
Proportion
VanEck Biotech ETF
9.71%
ProShares Ultra Nasdaq Biotechnology
8.83%
Invesco Nasdaq Biotechnology ETF
8.76%
iShares Biotechnology ETF
7.43%
Invesco Biotechnology & Genome ETF
5.35%
Natixis Loomis Sayles Focused Growth ETF
4.48%
First Trust NASDAQ Pharmaceuticals ETF
4.23%
First Trust NYSE Arca Biotechnology Index Fund
3.5%
Franklin Genomic Advancements ETF
3.33%
Simplify Health Care ETF
3.25%
View more
VanEck Biotech ETF
Proportion9.71%
ProShares Ultra Nasdaq Biotechnology
Proportion8.83%
Invesco Nasdaq Biotechnology ETF
Proportion8.76%
iShares Biotechnology ETF
Proportion7.43%
Invesco Biotechnology & Genome ETF
Proportion5.35%
Natixis Loomis Sayles Focused Growth ETF
Proportion4.48%
First Trust NASDAQ Pharmaceuticals ETF
Proportion4.23%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.5%
Franklin Genomic Advancements ETF
Proportion3.33%
Simplify Health Care ETF
Proportion3.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
